



Long-term efficacy and safety of pre-emptive maintenance therapy with Rituximab in 
Granulomatosis with polyangiitis: results from a single centre. 
 
Introduction 
Granulomatosis with polyangiitis (GPA) is a clinicopathologic variant of anti-
neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), with a distinct 
association with the presence of ANCA, directed against proteinase 3 (PR3) and 
myeloperoxidase (MPO) [1]. The spectrum of GPA comprises necrotizing granulomatous 
inflammation usually involving the upper and lower respiratory tract, a necrotizing vasculitis 
affecting predominantly small to medium vessels and commonly a necrotizing 
glomerulonephritis [1].  
GPA can rapidly lead to the development of severe organ damage and death but the overall 
prognosis of GPA has improved dramatically since the introduction of immunosuppressive 
drugs (ID) in induction and maintenance therapy. Cyclophosphamide (CYC) has evolved as 
the standard of care but has serious side effects – from infertility, typical and atypical 
infections, solid and non-solid malignancies, bone marrow toxicity, to hemorrhagic cystitis - 
and therefore other treatments are actively sought [2]. TNFα inhibitor agents have been 
unsuccessful and even detrimental in treating GPA [3]. Rituximab (RTX), a chimeric 
monoclonal antibody against CD20 that induces selective antibody-dependent and 
complement- mediated cellular cytotoxicity with subsequent apoptosis and elimination of B-
cells, has demonstrated efficacy in both the induction [4,5] and maintenance of remission in 
GPA [6-10]. While seemingly having few side effects, the long-term outcome after RTX 
therapy has not yet been described and safety issues concerning hypogammaglobulinemia and 




efficacy and safety data from a single centre in GPA patients treated during a median of 





Since 2001 the vasculitis disease registry (Nordnorsk Vaskulittregister) - approved by the 
Regional Ethical Committee (REK V 41/2001) - has collected information on disease 
presentation and course from patients with an established diagnosis of primary vasculitis 
followed at the University Hospital of North Norway. Subjects written consent was obtained 
according to the declaration of Helsinki and this study conforms to the standards currently 
applied in Norway. 
This analysis concerns 35 GPA patients from that registry, who were consecutively treated 
with RTX between April 2004 and September 2011. All patients satisfied the American 
College of Rheumatology 1990 classification criteria and/or Chapel Hill consensus 
conference criteria [12,13]. RTX was initially administered as two 1-gram infusions 2 weeks 
apart with co-administration of methylprednisolone 125 mg, paracetamol 1000 mg and either 
cetirizine 10 mg or polaramine 4 mg (rheumatoid arthritis protocol). Due to the observed RTX 
efficacy and the relapsing nature of GPA, RTX was subsequently re-administered in a pre-
emptive attempt to maintain B cell depletion. Patients received either 1g-infusion biannually 
or two 1-gram infusions 2 weeks apart annually. The 1g-infusion biannually became the 
preferred regimen as this was found to better sustain B cell depletion. 
Prior to RTX, most patients were treated with intravenous methylprednisolone 750-1000 mg 
daily for 3 days, followed by a daily oral prednisolone dose of 0.5-1mg/kg that was tapered to 
5-10 mg by 6 months. RTX was usually added to an ID (other than prednisolone) – mostly 
methotrexate (MTX), azathioprine (AZA), mycophenolate mofetil (MMF) and CYC. 
Discontinuation of prednisolone and ID during RTX remission maintenance relied upon the 
discretion of the treating physician. Ongoing treatments at RTX initiation and at last visit as 




Patients were seen 3 months after diagnosis and then every 6 months with extra visits in case 
of suspected relapse. Remission was assessed at every patient visit. Clinical examination, 
disease activity determined by the Birmingham Vasculitis Activity Score (BVAS 2003), a 
fixed set of blood tests (including ANCA, immunoglobulin (Ig) classes quantification and 
flow cytometric immunophenotyping of lymphocytes) as well as urine examinations were 
performed at all patient visits. If needed, radiology investigation of the involved organs and 
others system-specific clinical investigation were performed.  
Complete remission was defined as the absence of disease activity attributable to active 
vasculitis based on clinical judgement and with a BVAS score of 0. Partial remissions were 
defined as a decrease of at least 50% from baseline BVAS score without any signs of 
deterioration. Relapses were defined by the recurrence, worsening or first appearance of ≥1 
BVAS items attributable to GPA after remission. Grumbling disease was defined clinically as 
persisting symptoms not attributable to damage (such as arthralgia, fatigue, low-grade nasal 
crusting) in patients seemingly in remission [14].  
Immunoglobulins levels at last visit reflect data recorded either at last visit before 30th 
September 2011 (closing date of this database) regardless of ongoing therapy - or shortly 
before the first administration of intravenous immunoglobulins (IVIG). Nadir levels of total 
Ig, IgG, IgA and IgM during RTX maintenance were also recorded. Ig decline after the first 
RTX round (difference between levels before the first and the second RTX round) and their 
overall decline during maintenance (difference between levels at baseline and at last visit) 
were calculated. Hypogammaglobulinemia was defined as total Ig under 6 g/L and decision to 
start supplemental treatment with IVIG was based on clinical judgement taking in account if 





Severe adverse events – including infections, malignancy and bone marrow toxicity - were 
recorded, irrespective of a possible association with vasculitis and/or therapy. Infections were 
regarded as either severe or chronic infections. Severe infections were defined as necessitating 
hospitalisation and intravenous antibiotics treatment. Chronic infections were defined as 
symptomatic localized infections lasting 3 months or more and requiring several antibiotic 
courses.  
Trimetoprim-sulfamethoxazole (TMP-SMX) was not prescribed routinely during RTX 
maintenance. 
Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago, IL, USA). Results are 
expressed as actual values for categorical variables and as median (range) for continuous 
variables. Pearson chi-square, Mann-Whitney U tests were used as appropriate. Significant 
predictor variables for infections in univariate analysis were entered into a multivariate binary 
(backward stepwise, p <0.05 to enter, p< 0.10 to stay) logistic regression model. P-values < 






Thirty-five patients with GPA were included with disease duration of 55 months (1-270) 
before RTX initiation (Table 1). Thirty patients (86%) were ANCA positive at diagnosis. 
Twenty-one patients (60 %) had renal involvement; 22 patients (63%) had lung involvement 
and 20 patients (57%) had either orbital, subglottic or both involvements. Prior to RTX 
initiation, patients had used 3 (1-8) ID and a total cumulative dose CYC of 14.8 (0-250) 
grams. The relapse rate prior to RTX treatment was 30.9 / 100 patient-years observation.  
Patients were given RTX for disease relapse (28 patients), new onset disease (6 patients) and 
maintenance in one patient because of increasing high PR3-ANCA titer 6 months after 
induction with methotrexate (MTX). Almost all the patients received RTX in combination 
with another ID: only three patients were treated with RTX in monotherapy for relapse.  
Baseline BVAS was 9 (0-22). Ten patients (29%) had low IgM (<0.4 g/L) and 8 patients 
(23%) had low IgG (<7.0 g/L) serum levels while none had low IgA (<0.7g/L) levels or 
hypogammaglobulinemia (<6.0 g/L). Sixteen patients (46%) were still PR3-ANCA positive.  
Patients received a cumulative RTX dose of 8 (2-13) grams given over five (1-10) rounds and 
were followed for 47 (2-88) months after RTX initiation.  
 
Patients’ outcome  
 Remission and treatment failures 
Six months after RTX initiation, 29 patients (83%) had achieved complete remission and 4 
patients (11%) partial remission with an overall BVAS score of 0 (0-8) (See supplemental 
Table 1). Two patients were not in remission at 6 months but achieved complete remission at 
12 months. At last visit, 97% were in remission and one patient had grumbling disease with a 




Nine relapses occurred during 1636 months (136 years) of follow-up translating into a flare 
rate of 6.6 /100 patient-years observation. Relapses appeared 18 (7-75) months after RTX 
initiation and 15 (6-24) months after last RTX round. Five relapses occurred after the first 
RTX round, 2 after the second round and 2 after the fourth round. Five relapses occurred in 
patients using concomitant ID (3 patients on MMF, 1 on MTX and 1 on AZA). B cells were 
undetectable (<0.01x109/L) in 2 relapses and both patients received concomitant ID. B cells 
had returned at the time of relapse in the remaining 7 cases with count of 0.16x109/L (0.03-
0.60x109L). ANCA rose prior to 3 out of 9 relapses: two patients seroconverted to ANCA 
positivity and the titer almost quadrupled in the third patient. All 9 relapses were re-treated 
with RTX inducing again remission. Two patients were also retreated with RTX for 
grumbling disease (BVAS =1) 40 months after its initiation while B-cells were still depleted 
and ANCA titers were negative. 
 
RTX discontinuation  
At last visit, RTX had been discontinued in 13 patients (37%) for the following reasons (some 
patients had multiple causes): 8 patients for hypogammaglobulinemia (total Ig 4.71 g/L (3.51-
5.46)), 3 for severe infections, 4 for renal transplantation, 2 for malignancy, 2 for late-onset 
neutropenia, 1 for colitis and 1 for pregnancy. RTX was discontinued a median of 41 (12-78) 
months after its initiation and it had been discontinued a median of 14.5 (2-28) months at last 
visit. None of the patients that discontinued RTX had relapsed at last visit. 
Four of the 8 patients that discontinued RTX because of hypogammaglobulinemia received 
IVIG: total Ig before IVIG was lower in patients treated with IVIG 4.1 g/L (3.51-5.24) 
compared with 5.43 g/L (4.14-6.22) in those not treated with IVIG even though it was not 




Two patients died, both 28 months after RTX initiation. One patient died from bowel 
obstruction and Escherichia coli sepsis secondary to colonic cancer. The other patient died 
from sepsis without an identifiable agent complicating a myeloproliferative malignancy 
secondary to a high cumulative CYC dose (250 grams).   
 
Other immunomodulating medication at last visit: 
At last visit, 22 patients (63%) were still treated with RTX. Nineteen patients (86%) were 
maintained on RTX monotherapy while 3 patients (14%) were on ID: one patient received 
MMF 500mg daily, one patient used MTX 15mg weekly for control of his skin psoriasis and 
another used IVIG for hypogammaglobulinemia complicated with infection at last visit. 
Patients had used concomitant ID under RTX maintenance for 22 (1-54) months but had 
discontinued their ID 28 (1-50) months before last visit.  
In contrast, 8 of the 13 (62%) of patients that had discontinued RTX were still treated with 
other ID regimens at last visit. Four patients with renal transplantation received either 
tacrolimus or cyclosporine, in combination with MMF for 3 of them. Four patients were 
receiving IVIG at last visit for hypogammaglobulinemia. Two patients had died and 3 patients 
were off ID at last visit: 2 because of ongoing infection and 1 due to pregnancy.   
The median daily oral dose of Prednisolone decreased from 22.5mg (0-60) at RTX initiation 
to 5mg (0-30) at last visit. Seven patients (21%) had been off Prednisolone for 31 (8-60) 
months at last visit. 
Of interest, a total of five patients were treated with IVIG in the study period 41 (37-82) 
months from RTX initiation and between 6 and 12 months after the last RTX infusion. Total 
Ig was 4.51g/L (3.51-5.46) in these patients prior to IVIG. Hypogammaglobulinemia was 




patient received preventive IVIG because of severe hypogammaglobulinemia (total Ig 3.51 
g/L). Two of these patients were re-treated with RTX after receiving IVIG. 
 
Risk for infections 
 Severe infections 
Nine patients (26%) had severe infections necessitating hospitalization and intravenous 
therapy 29 (4-59) months after RTX initiation. The rate for severe infection was 6.6 /100 
patient-years observation. Five patients had pneumonia - due to cytomegalovirus, influenza B 
virus, Pneumocystis jiroveci, Staphylococcus aureus and an unidentified agent in one patient 
each. Two patients had gastrointestinal infections: one with Clostridium difficile colitis, the 
other with Escherichia coli complicating bowel obstruction. One patient developed Herpes-
Zoster infection and one was treated for Pseudomonas aeruginosa sinusitis. 
Patients with severe infections were older at RTX initiation (60 years vs 48.5 years; p=0.031) 
and all had renal involvement (OR=11.2; p=0.001), whereas the risk for severe infection was 
decreased in patients with orbital and subglottic involvements (OR=0.16; p=0.013). 
Patients with severe infections had received a higher cumulative CYC dose and had lower 
levels of total Ig during RTX maintenance and at last visit. Patients with severe infections had 
more profound decline in total Ig after the first RTX round and during RTX maintenance. 
Patients with severe infections had lower CD4 cell count at last visit, lower CD4/CD8 ratio 
both prior RTX and at last visit.  (See supplemental Table 2 for the complete analysis with 
Mann-Whitney U test).  
A higher cumulative dose of CYC, larger decreases in IgG, IgM and total Ig after the first 
RTX round as well as lower CD4 levels at last visit increased the risk for severe infections by 
univariate analysis (Table 2). Multivariate analysis using binary logistic regression showed 




larger decrease of total Ig after the first RTX round (p=0.040) were independently associated 
with severe infections. Larger decrease of total Ig after the first round was the most important 
independent risk factor for severe infections (OR=2.38 p=0.040) (Table 2). A 10 grams 
increase of the cumulative dose of CYC gave a proportionate change in odds of 2.38 
 Chronic infections 
Ten patients (29%) had chronic and relapsing infections (some patients had 2 chronic 
infections): 5 had bronchitis, 3 sinusitis, 2 pneumonia, 1 urethritis, 1 prostatitis, 1 
gastroenteritis with chronic diarrhea. 
Chronic infections were not increased with older age and in patients with either renal, 
pulmonary or orbital-subglottic involvement. 
Neither the cumulative CYC dose, the daily oral Prednisolone dose at last visit, the 
cumulative RTX dose nor the number of rounds of RTX was associated with chronic 
infections. Lower serum levels of total Ig, IgG, and IgM at nadir and at last visit increased the 
risk for chronic infections. In patients with chronic infections B cells counts at RTX initiation 
were lower, although with borderline significance. (See supplemental Table 3 for the 
complete analysis with Mann-Whitney U test).  
Lower IgM, IgG, total Ig both at nadir under RTX maintenance and at last visit - and possibly 
the cumulative dose and number of rounds of RTX - were risk factors for chronic infections 
by univariate analysis (Table 3). But low IgG at nadir was the only independent risk factor for 





In this Norwegian GPA cohort study RTX was an effective therapy for remission induction 
and long-term pre-emptive RTX maintenance reduced the relapse rate from 30.9 to 6.6 
relapses /100 patient-years. Our relapse rate under RTX maintenance is lower than the flare 
rates of 8 and 18/100 patient-years under AZA maintenance observed in the Cyclops study 
with induction with either daily oral or intravenous pulse of CYC [15]. It is also lower than 
the flare rate of 13.8 from the study of Cartin-Ceba et al [10]; however patients in this study 
had only relapsed after the first remission induction and did not relapse subsequently under a 
long-term RTX maintenance strategy based on serial B lymphocytes and PR3-ANCA testing 
[10]. In the study of Smith et al eighteen out of 61 patients (30%) with refractory/relapsing 
AAV had relapsed at 48 months during a 2 years fixed interval RTX re-treatment strategy [9]. 
Although fewer patients (23%) relapsed in our study, long-term pre-emptive six monthly re-
treatment with RTX does not seem to be greatly superior to the two-year fixed interval RTX 
re-treatment strategy [9] and the long-term pre-emptive RTX re-treatment strategy based on 
serial B lymphocytes and PR3-ANCA testing [10] in term of relapse. 
However our relapse rate under RTX maintenance is higher when compared to other RTX 
maintenance studies: Roubaud-Baudron et al [8] observed flare rate of 2.0 and Rhee et al of 
5.0 [7]. This difference is likely explained by a higher prevalence of granulomatous disease 
with orbital and subglottic involvements among our patients (57%), which are generally more 
prone to relapses [16].  
Maintenance therapy with RTX permitted both the withdrawal of concomitant ID and the 
reduction of the daily prednisolone dose in almost all our patients. This clinically important 
result is similar to other studies [6-9]. The return of B cells and the rise of ANCA did not 




In our study, 13 patients (37%) had discontinued RTX treatment after a median of 41 months 
mainly due to the occurrence of hypogammaglobulinemia and / or infections. These patients 
have been followed for 14.5 months (2-28) after discontinuation and none have relapsed so 
far. This confirms the findings of Smith et al that the risk for relapses remains reduced after 
RTX withdrawal [9].  
 
Given the importance of B cells in the surveillance against microbes, it is not surprising that 
long term B cell depletion will result in an increased risk of infectious complications as 
clearly shown here. Smith et al reported that 27% of the patients receiving routine RTX re-
treatment for 2 years had a total of 44 infections – a total of 2.6 infections per patients and 
found that the risk of severe infections during RTX maintenance was similar to that observed 
in patients treated with mycophenolate mofetil, alemtuzumab and deoxyspergulin [9]. In our 
study we distinguished between severe and chronic infections and 26% of our patients had 
severe infections alike the study of Smith et al. Thus long-term pre-emptive re-treatment with 
RTX does not seem to increase the risk for infections compared to the two-year fixed interval 
RTX re-treatment strategy proposed by Smith et al [9]. Nine patients (29%) were defined 
clinically as having a chronic infection that often lacked microbiological evidence and for 
which no comparative data are available.  
In our study the risk of severe infections was increased with older age, renal involvement, a 
high CYC cumulative dose, T cells defect and low total of immunoglobulins. These findings 
are not new as these same risk factors are known to increase the risk for severe infections 
when using CYC especially early in the course of the disease [17]. Of interest, the infectious 





Our severe infection rate is similar to the result from the German registry (6.5 per 100 patient-
years observation) that has a shorter follow-up time [18] and it has not increased during long-
term pre-emptive RTX maintenance therapy in our study. The risk for severe infections seems 
mostly conditioned by important decreases in Ig especially after the first RTX round (as 
shown in our study) and concurrent medication such as CYC and MMF. Two studies report 
severe infection rates of 15.5 and 22.5 per 100 patient-years with a much shorter observation 
time with respectively 66% of the patients using CYC [19] and 75% using either CYC or 
MMF in combination with RTX [20]. Although there is no clear evidence for an increased 
risk of severe infections during long-term pre-emptive RTX maintenance, repeated treatment 
with RTX by further decreasing total immunoglobulins level as shown in our study and by 
influencing T cell immunity [21] can still potentially increase the risk for severe infections. 
The risk for chronic infections seems to be associated with higher cumulative dose of RTX 
and increases with lower serum levels of total Ig, IgG and IgM during RTX maintenance. But 
other factors, a high cumulative dose of CYC and the prolonged exposure to prednisolone, 
can also contribute in the genesis of the dysgammaglobulinemia prior to RTX [22-23].  
Even though our study was retrospective and lacked a control group, the longitudinal data was 
collected in a prospective manner in the form of a disease registry from a single tertiary care 
center. The relatively small numbers on the other hand make subgroup analyses prone to type 
II errors of not detecting significant differences.  
 
In conclusion, long-term pre-emptive RTX is efficacious in reducing the risk for relapse and 
allows withdrawal of other ID in GPA patients with a high prevalence of granulomatous 
disease and a high flare rate before RTX. However, long-term pre-emptive RTX maintenance 
had to be discontinued in 37% of our patients due to hypogammaglobulinemia and infections. 




beneficial in preventing hypogammaglobulinemia [24] and infections, not only at induction 
but also over time. The inherent trade-off between relapse and infection risks in GPA 
management seems to be more predictable and manageable with RTX than with other ID as 






Long-term pre-emptive rituximab is efficacious in reducing the risk for relapse. 
After four years, 37% of the patients discontinued rituximab due to hypogammaglobulinemia 
and infections. 
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Characteristics of study cohort patients with Granulomatosis with polyangiitis (GPA) treated 
with long term Rituximab. All figures indicate median values (range) unless otherwise 
indicated 
No. of patients 35 
No. Male / Female 16  /  19 
Age (years)  
at diagnosis 




Disease duration before RTX (months) 55 (1-270) 
No of patients with ANCA positive at diagnosis 
Type PR3 / MPO  
30 (86%) 
29 / 1 
No of patients with ANCA positive prior RTX 
Type PR3 / MPO  
16 / 35 (46%) 
16 / 0 
No of patients with orbital or subglottic involvement 20 (57%) 
 
No of patients with renal involvement 
No of patients with pulmonary involvement 
21 (60%) 
22 (63%) 
Number of previous immunosuppressive drugs prior 
RTX 
3 (1-8) 
Prednisolone dose at RTX initiation (mg) 22.5 (0-60) 
Cumulative Cyclophosphamide dose (g)  14.8 (0-250) 
No of RTX for maintenance / new disease / relapse 1 / 6 / 28 
BVAS at RTX initiation 9 (0-22) 
RTX cumulative dose (g) 
No of RTX rounds 
8 (2-13) 
5 (1-10) 
Follow-up after RTX initiation (months) 47 (2-88) 
ANCA: anti-neutrophil cytoplasmic antibodies; BVAS: Birmingham Vasculitis Activity 





Risk factors for severe infections in our study cohort determined by univariate and 
multivariate (backward stepwise) binary logistic regression analysis. All predictor variables in 
this analysis are continuous. 












upper 95% CI 
Age (years) 1.06 0.059 0.99-1.14    
Cumulative dose of 
CYC (g) 
1.04 0.036 1.00-1.08 1.09 0.037 1.01-1.18 
Prednisolone dose at LV 
(mg) 
1.18 0.055 0.99-1.39    
IgA level at nadir (g/L) 0.07 0.050 0.01-1.00  0.341  
CD4/CD8 ratio prior 
RTX 
0.24 0.076 0.05-1.16    
CD4/CD8 ratio at LV 0.31 0.070 0.09-1.10    
Total CD4 cells at LV 
(x109/L) 
0.002 0.016 0.001-0.33  0.045  
IgG decline after 1. 
round (g/L) 
1.78 0.038 1.03-3.06    
IgM decline after 1. 
round (g/L) 
53.3 0.026 1.63-1740    
Total Ig decline after 1. 
round (g/L) 
1.81 0.023 1.09-3.01 2.38 0.040 1.04-5.46 
Total Ig overall decline  
(g/L) 
1.33 0.064 0.98-1.78    
 
CI: confidence interval; CYC: cyclophosphamide; CD: cluster of differentiation; Ig: 






Risk factors for chronic infections in our study cohort determined by univariate and 
multivariate (backward stepwise) binary logistic regression. All predictor variables in this 
analysis are continuous. 











Lower and upper 
95% CI 
Number of RTX 
rounds  
1.43 0.061 0.98-2.07    
Cumulative RTX 
dose (g) 
1.30 0.075 0.97-1.73 1.40 0.095 0.94-2.06 
IgG level at nadir 
(g/L) 
0.48 0.023 0.26-0.91 0.43 0.026 0.21-0.90 
IgM level at nadir 
(g/L) 
0.001 0.039 0.001-0.67  0.264  
Total Ig level at 
nadir (g/L) 
0.62 0.038 0.39-0.98    
IgG level at LV (g/L) 0.53 0.036 0.30-0.96    
IgM level at LV (g/L) 0.001 0.025 0.001-0.39    
Total Ig level at LV 
(g/L) 
0.64 0.042 0.41-0.98    
 




Online supplementary data  
Supplementary Table 1 
Patients’ outcome after long-term pre-emptive rituximab maintenance therapy. All figures 
indicate median values (range) unless otherwise indicated 
At 6 months 
No. of patients in remission* 





29 (83%) – 4 (11%) 
0 (0-8) 
At last visit 
No. of patients in remission# 




25 (76%) – 7 (21%) 
0 (0-5) 
Prednisolone dose at last visit (mg) 5 (0-30) 
 
No. of patients treated with ID at last visit (other than RTX and 
prednisolone) 
7 / 33 (21 %) 
 
 
No. of patients with relapse under RTX  8 / 35 (23%) 
1 patient with 2 
relapses. 
No. of patients with RTX discontinuation at last visit 
No. of patients that discontinued due to hypogammaglobulinemia 
(<6g/L) 
13 / 35 (37%) 
8 / 13 (62%) 
 
 
No of patients treated with IVIG 5 / 35 (14%) 
 
No. of patients with  




10 / 35 (29%) 
9 / 35 (26%) 
2 / 35 (5.7%) 
 
BVAS: Birmingham Vasculitis Activity Score; ID: immunosuppressive drugs; IVIG: intra-
venous immunoglobulins; RTX: rituximab. 
* Two patients were not in remission at 6 months, but were in remission at 12 months. 




Supplementary Table 2 
Difference in medians between patients with and without severe infections; p-values 
calculated by non-parametric significance test -Mann Whitney U test. All predictor variables 
in this analysis are continuous.  
 Patients with severe 
infection 




CYC cumulative dose (g) 51.7 13.0 0.045 
Daily prednisolone dose at LV 
(mg) 
5 5 0.024 
RTX cumulative dose (g) 6 8.5 0.110 
Number of RTX rounds 5 5.5 0.446 
Total Ig at nadir (g/L) 4.7 6.7 0.018 
IgG at nadir (g/L)  3.7 5.7 0.015 
IgA at nadir (g/L) 0.82 1.1 0.038 
Total Ig at LV (g/L) 5.4 7.4 0.031 
IgG at LV (g/L) 4.4 6.0 0.046 
IgG decline after 1. round• (g/L) 3.0 1.4 0.013 
IgM decline after 1. round• (g/L) 0.71 0.21 0.001 
Total Ig decline after 1. round• 
(g/L) 
4.3 1.7 0.005 
Total Ig overall decline* (g/L) 5.6 2.9 0.001 
IgG overall decline* (g/L)  4.3 2.2 0.016 
CD4/CD8 ratio prior RTX 0.84 1.26 0.023 
CD4/CD8 ratio at LV 0.72 1.67 0.025 
CD4 cells count at LV (x109/L) 0.25 0.67 0.002 
 
CD: cluster of differentiation; CYC: cyclophosphamide; Ig: immunoglobulins; LV: last visit; RTX: rituximab 
* Ig overall decline corresponds to the absolute change in Ig levels between baseline and last visit. 





Supplementary Table 3 
Difference in medians between patients with and without chronic infections; p-values 
calculated by non-parametric Mann Whitney U test. All predictor variables in this analysis are 
continuous. 
 Patients with chronic 
infection 




CYC cumulative dose (g) 17.1 14.8 0.867 
Daily prednisolone dose at 
LV (mg) 
5.0 5.0 0.669 
RTX cumulative dose (g) 8.5 7 0.113 
Number of RTX rounds 6.5 5 0.113 
Total Ig at nadir (g/L) 5.7 7.5 0.019 
IgG at nadir (g/L)  4.1 6.2 0.013 
IgM at nadir (g/L)  0.13 0.33 0.012 
Total Ig at LV (g/L) 5.7 8.7 0.019 
IgG at LV (g/L) 4.4 6.2 0.013 
Total IgM at LV (g/L) 0.16 0.35 0.007 
B cells count prior RTX 
(x109/L) 
0.035 0.09 0.065 
 
CYC: cyclophosphamide; Ig: immunoglobulins; LV: last visit; RTX: rituximab 
 
 
